Felstead S J, Daniel R
Department of Clinical Research, Pfizer Central Research, Sandwich, UK.
J Int Med Res. 1991 Sep-Oct;19(5):363-72. doi: 10.1177/030006059101900502.
In two randomized, multicentre studies patients with upper respiratory tract infections treated with 1.5 g azithromycin in five or six doses over 5 days were compared with patients treated with 10 g erythromycin in 40 doses over 10 days or 15 g amoxycillin in 30 doses over 10 days. The majority of azithromycin- (65%) and erythromycin- (67%) treated patients in the azithromycin/erythromycin study and all patients in the azithromycin/amoxycillin study had sinusitis. Clinical cure was recorded in 83% of azithromycin- and 79% of erythromycin-treated patients, and in 81% and 87%, respectively, of azithromycin- and amoxycillin-treated patients. There was no significant difference in bacteriological eradication between the treatments. Adverse events, predominantly mild or moderate gastro-intestinal complaints, occurred in 17% and 15%, respectively, of azithromycin- and erythromycin-treated patients, and in 5% and 11%, respectively, of azithromycin- and amoxycillin-treated patients but there were no serious laboratory safety abnormalities. Azithromycin appeared to be an effective, simplified treatment for upper respiratory tract infections and may improve patient compliance compared with standard therapies.
在两项随机、多中心研究中，将5天内分五或六剂服用1.5克阿奇霉素治疗上呼吸道感染的患者，与10天内分40剂服用10克红霉素或10天内分30剂服用15克阿莫西林治疗的患者进行了比较。在阿奇霉素/红霉素研究中，大多数接受阿奇霉素治疗的患者（65%）和接受红霉素治疗的患者（67%）以及阿奇霉素/阿莫西林研究中的所有患者都患有鼻窦炎。接受阿奇霉素治疗的患者中有83%、接受红霉素治疗的患者中有79%记录了临床治愈，接受阿奇霉素治疗的患者和接受阿莫西林治疗的患者中分别有81%和87%记录了临床治愈。各治疗组之间的细菌清除率没有显著差异。不良事件主要为轻度或中度胃肠道不适，接受阿奇霉素治疗的患者和接受红霉素治疗的患者中分别有17%和15%出现不良事件，接受阿奇霉素治疗的患者和接受阿莫西林治疗的患者中分别有5%和11%出现不良事件，但没有严重的实验室安全异常情况。与标准疗法相比，阿奇霉素似乎是一种有效的、简化的上呼吸道感染治疗方法，可能会提高患者的依从性。
